SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): February 10, 2010
Derma
Sciences, Inc.
(Exact name of registrant as specified
in its charter)
Pennsylvania
|
1-31070
|
23-2328753
|
(State
or other jurisdiction
|
(Commission
|
(IRS
employer
|
of
incorporation)
|
File
Number)
|
identification
number)
|
214
Carnegie Center, Suite 300
Princeton,
NJ 08540
(609)
514-4744
(Address
including zip code and telephone
number,
of principal executive offices)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
¨ Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01 Other Events
Effective
February 10, 2010, the common stock, par value $0.01 per share, of Derma
Sciences, Inc. (the “Registrant”), was listed on the NASDAQ Capital
Market.
The Registrant’s press release issued
February 9, 2010 relative to the NASDAQ listing is attached hereto as Exhibit
99.
Item
9.01 Financial Statements and Exhibits
99 –
Press Release
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.
DERMA
SCIENCES, INC.
|
|
By:
|
/s/John E.
Yetter
|
|
John
E. Yetter, CPA
|
|
Vice
President and Chief Financial
Officer
|
Date: February
11, 2010